Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Saved in:
Bibliographic Details
Title: Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.
Authors: Ahrens M; Medical Clinic II, Goethe University, Frankfurt, Germany., Haanen J; Netherlands Cancer Institute, Amsterdam and Leiden University Medical Center, Leiden, Netherlands; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Albiges L; Institut Gustave Roussy, Paris, France., Goupil MG; Department of Medical Oncology, University Hospital Bordeaux, Bordeaux, France., Boleti E; Royal Free London NHS Foundation Trust, London, UK., Gravis G; Department of Medical Oncology, Institut Paoli-Calmettes, Aix Marseille Univ, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France., Fléchon A; Department of Urology, Jena University Hospital, Friedrich-Schiller University and Comprehensive Cancer Center Germany (CCCG), Jena, Germany., Grimm MO; Centre Léon Bérard, Lyon, France., Bedke J; Clinic for Urology, University Hospital, Tuebingen, Germany and Dept. of Urology & Transplantation Surgery, Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany., Barthélémy P; Hôpitaux Universitaires de Strasbourg, Strasbourg, France., Castellano D; Clinic of Oncology, Hospital Universitario 12 de Octobre, Madrid, Spain., Mellado B; Clinic for Oncology Hospital Clinic de, Barcelona, Spain., Ivanyi P; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Claudia von Schelling Comprehensive Cancer Center, Hannover, Germany., Rottey S; Ghent University Hospital, Ghent, Belgium., Flörcken A; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and, Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany., Suárez C; Hospital Universitari Vall d´Hebron, Vall d´Hebron Barcelona Hospital Campus, Medical Oncology, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain., Maroto JP; Sant Pau Hospital (Hospital de la Santa Creu i Sant Pau), Barcelona, Spain., Grünwald V; Clinic for Urology and Clinic for Medical Oncology, University Hospital, Essen, Germany., Oosting S; University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands., Kopecky J; Faculty Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Zschäbitz S; University Hospital, NCT Heidelberg, Heidelberg, Germany., Boegemann M; University Hospital Münster, Clinic for Urology, Münster, Germany., Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and, Thomayer University Hospital, Prague, Czech Republic., Niegisch G; Department of Urology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, Düsseldorf, and, Centre for Integrated Oncology (CIO) Düsseldorf, CIO ABCD (Aachen-Bonn-Cologne-Düsseldorf), Düsseldorf, Düsseldorf, Germany., Goebell PJ; Erlangen University Hospital, Department of Urology and Pediatric Urology, Erlangen, Germany., Waddell T; The Christie NHS Foundation Trust, Manchester, UK., Joly F; Centre Régional de Lutte contre le Cancer François Baclesse, Caen, France., Priou F; Hospital Center Departmental De Vendée, La-Roche-sur-Yon, France., Retz M; Technical University of Munich, School of Medicine and Health, Department of Urology, TUM University Hospital, Munich, Germany., Siemer S; Department of Urology, Saarland University, Homburg/Saar, Germany., Zimmermann U; University Medical Center Greifswald, Clinic for Urology, Greifswald, Germany., Deckbar D; Medical Clinic II, Goethe University, Frankfurt, Germany., Burkholder I; Department of Health Sciences, Fulda University of Applied Sciences, Fulda, Germany., Hartmann A; Institute of Pathology University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Bergmann L; Medical Clinic II, Goethe University, Frankfurt, Germany. Electronic address: l.bergmann@em.uni-frankfurt.de.
Corporate Authors: Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN)
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2026 May 27; Vol. 243, pp. 116816. Date of Electronic Publication: 2026 May 27.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2026.116816